WO2007046893A3 - Methods for generating bioactive assemblies and uses thereof - Google Patents

Methods for generating bioactive assemblies and uses thereof Download PDF

Info

Publication number
WO2007046893A3
WO2007046893A3 PCT/US2006/025499 US2006025499W WO2007046893A3 WO 2007046893 A3 WO2007046893 A3 WO 2007046893A3 US 2006025499 W US2006025499 W US 2006025499W WO 2007046893 A3 WO2007046893 A3 WO 2007046893A3
Authority
WO
WIPO (PCT)
Prior art keywords
ddd
assembly
attached
bioactive
assemblies
Prior art date
Application number
PCT/US2006/025499
Other languages
French (fr)
Other versions
WO2007046893A2 (en
Inventor
Chien Hsing Chang
David M Goldenberg
William J Mcbride
Edmund A Rossi
Original Assignee
Ibc Pharmaceuticals Inc
Chien Hsing Chang
David M Goldenberg
William J Mcbride
Edmund A Rossi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/389,358 external-priority patent/US7550143B2/en
Priority claimed from PCT/US2006/010762 external-priority patent/WO2006107617A2/en
Priority claimed from PCT/US2006/012084 external-priority patent/WO2006107786A2/en
Application filed by Ibc Pharmaceuticals Inc, Chien Hsing Chang, David M Goldenberg, William J Mcbride, Edmund A Rossi filed Critical Ibc Pharmaceuticals Inc
Priority to EP06785922A priority Critical patent/EP1937851A4/en
Priority to AU2006302848A priority patent/AU2006302848C1/en
Priority to JP2008536564A priority patent/JP5231231B2/en
Priority to CA2607056A priority patent/CA2607056C/en
Priority to CN201610087781.1A priority patent/CN105709237A/en
Priority to SG200904095-7A priority patent/SG153825A1/en
Priority to PCT/US2006/046367 priority patent/WO2007075270A2/en
Priority to CA2633486A priority patent/CA2633486C/en
Priority to CN201310087033.XA priority patent/CN103242451B/en
Priority to US11/633,729 priority patent/US7527787B2/en
Priority to AU2006330051A priority patent/AU2006330051B2/en
Priority to CN200680052809.2A priority patent/CN101374546B/en
Priority to EP06848816.2A priority patent/EP1959993B1/en
Priority to EP13004490.2A priority patent/EP2674440B1/en
Priority to KR1020087017349A priority patent/KR101410521B1/en
Priority to JP2008545643A priority patent/JP5090366B2/en
Publication of WO2007046893A2 publication Critical patent/WO2007046893A2/en
Priority to US11/925,408 priority patent/US7666400B2/en
Priority to HK08110462.0A priority patent/HK1117761A1/en
Priority to US12/396,605 priority patent/US7858070B2/en
Publication of WO2007046893A3 publication Critical patent/WO2007046893A3/en
Priority to US12/644,146 priority patent/US7981398B2/en
Priority to US12/731,781 priority patent/US8003111B2/en
Priority to US12/766,092 priority patent/US8067006B2/en
Priority to US12/871,345 priority patent/US8551480B2/en
Priority to US12/949,536 priority patent/US8211440B2/en
Priority to US13/150,613 priority patent/US8277817B2/en
Priority to US13/178,092 priority patent/US8158129B2/en
Priority to US13/246,389 priority patent/US8338140B2/en
Priority to US13/412,816 priority patent/US8435540B2/en
Priority to US13/483,761 priority patent/US20120276608A1/en
Priority to US13/589,575 priority patent/US9457100B2/en
Priority to US13/670,790 priority patent/US8889835B2/en
Priority to US13/688,812 priority patent/US8883162B2/en
Priority to US13/851,404 priority patent/US20130217091A1/en
Priority to US14/017,885 priority patent/US9481878B2/en
Priority to US14/505,595 priority patent/US9862770B2/en
Priority to US14/510,746 priority patent/US9707300B2/en
Priority to US14/598,664 priority patent/US9441043B2/en
Priority to US15/224,882 priority patent/US9751948B2/en
Priority to US15/247,386 priority patent/US9872920B2/en
Priority to US15/264,747 priority patent/US20160375108A1/en
Priority to US15/646,813 priority patent/US10377829B2/en
Priority to US15/827,637 priority patent/US20180079816A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)

Abstract

The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
PCT/US2006/025499 2004-02-13 2006-06-29 Methods for generating bioactive assemblies and uses thereof WO2007046893A2 (en)

Priority Applications (42)

Application Number Priority Date Filing Date Title
EP06785922A EP1937851A4 (en) 2005-10-19 2006-06-29 Methods and compositions for generating bioactive assemblies of increased complexity and uses
AU2006302848A AU2006302848C1 (en) 2005-10-19 2006-06-29 Methods and compositions for generating bioactive assemblies of increased complexity and uses
JP2008536564A JP5231231B2 (en) 2005-10-19 2006-06-29 Methods and compositions and uses for generating bioactive assemblies of increased complexity
CA2607056A CA2607056C (en) 2005-10-19 2006-06-29 Methods and compositions for generating bioactive assemblies of increased complexity and uses
EP13004490.2A EP2674440B1 (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
KR1020087017349A KR101410521B1 (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioacitive assemblies
JP2008545643A JP5090366B2 (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin bioactive assembly
SG200904095-7A SG153825A1 (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
AU2006330051A AU2006330051B2 (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
PCT/US2006/046367 WO2007075270A2 (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
CA2633486A CA2633486C (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
CN201310087033.XA CN103242451B (en) 2005-12-16 2006-12-05 Multivalence bioactive assemblies based on immunoglobulin
US11/633,729 US7527787B2 (en) 2005-10-19 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
CN201610087781.1A CN105709237A (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
CN200680052809.2A CN101374546B (en) 2005-12-16 2006-12-05 Based on the multivalence bioactive assemblies of immunoglobulin
EP06848816.2A EP1959993B1 (en) 2005-12-16 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies
US11/925,408 US7666400B2 (en) 2005-04-06 2007-10-26 PEGylation by the dock and lock (DNL) technique
HK08110462.0A HK1117761A1 (en) 2005-12-16 2008-09-22 Multivalent immunoglobulin-based bioactive assemblies
US12/396,605 US7858070B2 (en) 2005-10-19 2009-03-03 Multivalent immunoglobulin-based bioactive assemblies
US12/644,146 US7981398B2 (en) 2005-04-06 2009-12-22 PEGylation by the dock and lock (DNL) technique
US12/731,781 US8003111B2 (en) 2005-04-06 2010-03-25 Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US12/766,092 US8067006B2 (en) 2005-04-06 2010-04-23 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US12/871,345 US8551480B2 (en) 2004-02-13 2010-08-30 Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US12/949,536 US8211440B2 (en) 2005-10-19 2010-11-18 Multivalent immunoglobulin-based bioactive assemblies
US13/150,613 US8277817B2 (en) 2005-04-06 2011-06-01 PEGylation by the dock and lock (DNL) technique
US13/178,092 US8158129B2 (en) 2005-04-06 2011-07-07 Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
US13/246,389 US8338140B2 (en) 2005-04-06 2011-09-27 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US13/412,816 US8435540B2 (en) 2005-04-06 2012-03-06 Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO
US13/483,761 US20120276608A1 (en) 2005-10-19 2012-05-30 Multivalent Immunoglobulin-Based Bioactive Assemblies
US13/589,575 US9457100B2 (en) 2005-04-06 2012-08-20 PEGylation by the dock and lock (DNL) technique
US13/670,790 US8889835B2 (en) 2005-04-06 2012-11-07 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US13/688,812 US8883162B2 (en) 2005-10-19 2012-11-29 Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US13/851,404 US20130217091A1 (en) 2005-04-06 2013-03-27 Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo
US14/017,885 US9481878B2 (en) 2004-02-13 2013-09-04 Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US14/505,595 US9862770B2 (en) 2005-10-19 2014-10-03 Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US14/510,746 US9707300B2 (en) 2005-04-06 2014-10-09 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US14/598,664 US9441043B2 (en) 2005-12-16 2015-01-16 Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
US15/224,882 US9751948B2 (en) 2005-12-16 2016-08-01 Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
US15/247,386 US9872920B2 (en) 2005-04-06 2016-08-25 PEGylation by the dock and lock (DNL) technique
US15/264,747 US20160375108A1 (en) 2004-02-13 2016-09-14 Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
US15/646,813 US10377829B2 (en) 2005-12-16 2017-07-11 Isolated nucleic acid encoding an anti-IGF-1R antibody
US15/827,637 US20180079816A1 (en) 2005-10-19 2017-11-30 Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US60/728,292 2005-10-19
US75119605P 2005-12-16 2005-12-16
US60/751,196 2005-12-16
US78233206P 2006-03-14 2006-03-14
US60/782,332 2006-03-14
US11/389,358 US7550143B2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
PCT/US2006/010762 WO2006107617A2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
USPCT/US2006/010762 2006-03-24
US11/389,358 2006-03-24
US11/391,584 US7521056B2 (en) 2005-04-06 2006-03-28 Stably tethered structures of defined compositions with multiple functions or binding specificities
US11/391,584 2006-03-28
USPCT/US2006/012084 2006-03-29
PCT/US2006/012084 WO2006107786A2 (en) 2005-04-06 2006-03-29 Improved stably tethered structures of defined compositions with multiple functions or binding specificities

Related Parent Applications (5)

Application Number Title Priority Date Filing Date
US11/389,358 Continuation-In-Part US7550143B2 (en) 1999-05-10 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
PCT/US2006/012084 Continuation-In-Part WO2006107786A2 (en) 2004-02-13 2006-03-29 Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US11/478,021 Continuation-In-Part US7534866B2 (en) 1999-05-10 2006-06-29 Methods and compositions for generating bioactive assemblies of increased complexity and uses
US12/731,781 Continuation-In-Part US8003111B2 (en) 2004-02-13 2010-03-25 Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US12/766,092 Continuation-In-Part US8067006B2 (en) 2005-04-06 2010-04-23 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2006/010762 Continuation-In-Part WO2006107617A2 (en) 2004-02-13 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
PCT/US2006/012084 Continuation-In-Part WO2006107786A2 (en) 2004-02-13 2006-03-29 Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US11/478,021 Continuation-In-Part US7534866B2 (en) 1999-05-10 2006-06-29 Methods and compositions for generating bioactive assemblies of increased complexity and uses
US11/633,729 Continuation-In-Part US7527787B2 (en) 1999-05-10 2006-12-05 Multivalent immunoglobulin-based bioactive assemblies

Publications (2)

Publication Number Publication Date
WO2007046893A2 WO2007046893A2 (en) 2007-04-26
WO2007046893A3 true WO2007046893A3 (en) 2009-04-23

Family

ID=40666724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/025499 WO2007046893A2 (en) 2004-02-13 2006-06-29 Methods for generating bioactive assemblies and uses thereof

Country Status (5)

Country Link
EP (1) EP1937851A4 (en)
JP (1) JP5231231B2 (en)
AU (1) AU2006302848C1 (en)
CA (1) CA2607056C (en)
WO (1) WO2007046893A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US8883162B2 (en) 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
CN101138558B (en) * 2007-09-13 2010-08-25 汕头大学医学院 Pentamidine and death domain receptor ligand united application
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
US20110268757A1 (en) 2008-12-03 2011-11-03 Institut Pasteur Use of phenol-soluble modulins for vaccine development
WO2010091324A1 (en) * 2009-02-06 2010-08-12 Western States Biopharmaceuticals, Inc. Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
IN2012DN01331A (en) * 2009-08-31 2015-06-05 Ibc Pharmaceuticals Inc
IN2012DN01662A (en) * 2009-08-31 2015-06-05 Immunomedics Inc
EP2476440B1 (en) 2009-09-11 2017-08-02 Proyecto de Biomedicina Cima, S.L. Therapeutic compositions for the treatment of hpv-induced diseases
IN2012DN02692A (en) * 2009-11-05 2015-09-04 Ct Molecular Med & Immunology
AU2010328136B2 (en) * 2009-12-09 2016-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
CN102665757A (en) * 2009-12-09 2012-09-12 免疫医疗公司 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
JP5798125B2 (en) * 2009-12-15 2015-10-21 チェ，ムヒョン Method for producing dimers and multimers through increased formation of cross-links in complex chains of conjugates and multi-monomer complexes with binding specificity for monomers
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
IN2012DN05101A (en) * 2010-01-19 2015-10-23 Immunomedics Inc
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
EP2605788B1 (en) * 2010-08-17 2018-10-10 IBC Pharmaceuticals, Inc. Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
EP2635300A4 (en) * 2010-11-03 2014-04-02 Ibc Pharmaceuticals Inc Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CN103160513B (en) * 2011-12-16 2015-07-01 中国医学科学院基础医学研究所 MUC1 protein nucleic acid aptamer, complex, composition and purposes thereof
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
EP2854845B1 (en) 2012-06-01 2018-03-28 IBC Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
CN102703453B (en) * 2012-06-13 2013-10-30 江南大学 DNA aptamer specifically recognizing streptomycin and application of DNA aptamer
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc T-cell redirecting bispecific antibodies for treatment of disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
ITRM20130138A1 (en) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche ASSEMBLED INCLUDING A LIGHT ABSORBER IN THE INFRARED NEIGHBOR ENTITLELY TIED TO AN INHIBITOR OF THE CARBON DIVE
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
CA2924520C (en) 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
FR3017714A1 (en) * 2014-02-18 2015-08-21 Biomerieux Sa METHOD AND KIT FOR DETERMINING THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
TWI742423B (en) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
JP6602875B2 (en) 2015-01-26 2019-11-06 マクロジェニクス，インコーポレーテッド Multivalent molecule containing DR5 binding domain
CN104558174A (en) * 2015-01-29 2015-04-29 东南大学 Testosterone-orientated specific nano-antibody and application thereof
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3865139B1 (en) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016250570B2 (en) 2015-04-21 2021-07-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3303370A4 (en) 2015-05-28 2019-03-13 Immunomedics, Inc. T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
PL3328419T3 (en) 2015-07-30 2021-12-27 Macrogenics, Inc. Pd-1-binding molecules and methods of use thereof
RU2731202C2 (en) 2015-10-08 2020-08-31 Макродженикс, Инк. Combined therapy for cancer treatment
KR102106619B1 (en) * 2015-10-12 2020-05-06 진메디신 주식회사 Adenovirus complex for gene delivery and gene therapy
WO2017094897A1 (en) * 2015-12-04 2017-06-08 全薬工業株式会社 Anti-il-17 aptamer having improved retention in blood
KR102424513B1 (en) 2015-12-14 2022-07-25 마크로제닉스, 인크. Bispecific molecules with immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
EA038551B1 (en) 2015-12-17 2021-09-14 Дзе Джонс Хопкинс Юниверсити Method for treating or preventing systemic sclerosis
TW201730212A (en) 2016-02-17 2017-09-01 宏觀基因股份有限公司 ROR1-binding molecules, and methods of use thereof
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
KR102508650B1 (en) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 Compositions and methods for treating pancreatic cancer and pain with death receptor agonists
MX2018012433A (en) 2016-04-15 2019-03-01 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof.
AR110424A1 (en) 2016-12-23 2019-03-27 Macrogenics Inc ADAM9 BINDING MOLECULES AND SAME USE METHODS
CN110325209A (en) 2017-02-24 2019-10-11 宏观基因有限公司 CD137 and the bi-specific binding molecule of tumour antigen and application thereof can be combined
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN109771658B (en) * 2017-11-14 2021-12-10 博瑞生物医药（苏州）股份有限公司 Targeted multi-arm conjugates
MX2020006155A (en) 2017-12-12 2020-08-13 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease.
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
KR102101561B1 (en) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 Angiogenesis target constrast medium and a method for producing the same
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
WO2022010798A1 (en) 2020-07-06 2022-01-13 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CN112156194B (en) * 2020-09-29 2023-01-24 中国工程物理研究院核物理与化学研究所 Removing method 177 Method for endotoxin in Lu solution
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
CN115976196A (en) * 2022-12-16 2023-04-18 深圳市人民医院 Application of ErbB3 as pulmonary hypertension biomarker and therapeutic target

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868109A (en) * 1985-04-29 1989-09-19 Lansdorp Peter M Immunological antibody complex, its preparation and its use
WO1999066951A2 (en) * 1998-06-22 1999-12-29 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US20040086946A1 (en) * 2002-11-05 2004-05-06 Murphy Andrew J. Methods of isolation of active compounds and activated targets

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198956A1 (en) * 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US7060506B2 (en) * 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
CA2484676A1 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
JP2006518202A (en) * 2003-02-13 2006-08-10 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Rhesus monkey carcinoembryonic antigen, nucleotides encoding said antigen, and uses thereof
JP5011277B2 (en) * 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド Methods and uses for generating stably linked complexes consisting of homodimers, homotetramers or dimeric dimers
CA2633486C (en) * 2005-12-16 2015-02-03 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868109A (en) * 1985-04-29 1989-09-19 Lansdorp Peter M Immunological antibody complex, its preparation and its use
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
WO1999066951A2 (en) * 1998-06-22 1999-12-29 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20040086946A1 (en) * 2002-11-05 2004-05-06 Murphy Andrew J. Methods of isolation of active compounds and activated targets

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1937851A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US9359443B2 (en) 2005-04-06 2016-06-07 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases

Also Published As

Publication number Publication date
WO2007046893A2 (en) 2007-04-26
EP1937851A4 (en) 2010-08-25
CA2607056C (en) 2015-11-24
EP1937851A2 (en) 2008-07-02
AU2006302848A1 (en) 2007-04-26
JP2009517337A (en) 2009-04-30
CA2607056A1 (en) 2007-04-26
JP5231231B2 (en) 2013-07-10
AU2006302848B2 (en) 2012-02-23
AU2006302848C1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
WO2007046893A3 (en) Methods for generating bioactive assemblies and uses thereof
WO2007075270A3 (en) Multivalent immunoglobulin-based bioactive assemblies
WO2003068934A3 (en) Chimeric molecules for cleavage in a treated host
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
WO2008125269A3 (en) A toothbrush
WO2004009793A3 (en) Synthesis of glycoproteins using bacterial gycosyltransferases
WO2006031398A3 (en) Compositions containing fast-leaching plasticizers for improved performance of medical devices
WO2006038908A3 (en) Ancestral and cot viral sequences, proteins and immunogenic compositions
WO2007006041A3 (en) Imaging and therapeutic method using monocytes
EP2479191A3 (en) Improved nanobodiesTM against tumor necrosis factor-alpha
WO2009062195A3 (en) Fusion proteins of mannose binding lectins for treatment of disease
WO2008075040A3 (en) Radioactive pet agents for imaging ccr5 in vivo
WO2007118963A3 (en) Substituted n-(phenethyl)benzamide derivatives, preparation and uses thereof
WO2004048534A3 (en) Modulation of cytokine-inducible kinase expression
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2008017636A8 (en) Genes and proteins of brachyspira hyodysenteriae and uses thereof
WO2006108720A3 (en) Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
DE602007000448D1 (en) Surgical instrument with box joint and method for its manufacture
WO2006124545A3 (en) Methods, compositions, systems, and devices for bone fusion
WO2008105215A1 (en) Marker peptide for diagnosis of alcoholic liver disease, and method for diagnosis of alcoholic liver disease using the same
WO2005006958A8 (en) Modulation of ceacam1 expression
WO2004047741A3 (en) Modulation of iap-like expression

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680019869.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11633729

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11633729

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006302848

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 8041/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006785922

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008536564

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2607056

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE